The programme is preliminary and subject to change
Wednesday 07 May
Artificial intellegence and atherosclerosis: A glimpse into the future
Will AI cure Atherosclerotic Cardiovascular disease
Thomas Lüscher, Zürich, Switzerland
Thomas Lüscher, Zürich, Switzerland
UK Biobank: scale, depth, duration...but, most importantly, accessibility
Sir Rory Collins, Oxford, UK
Sir Rory Collins, Oxford, UK
Atherosclerosis phenotyping using artificial intelligence: implications for imaging
Ron Blankstein, Boston, USA
Ron Blankstein, Boston, USA
Gain unprecedented insights into CVD with the latest -omics technologies using generative AI
Manuel Mayr, London, UK
Manuel Mayr, London, UK
Tuesday 06 May
Non-traditional risk factors for atherosclerosis
Environmental pollution: a modifiable risk factor?
Thomas Münzel, Mainz, Germany
Thomas Münzel, Mainz, Germany
Immunometabolism as driving force of atherosclerosis
Kathryn Moore, New York, USA
Kathryn Moore, New York, USA
Per particle importance of remnants vs. Lp(a) vs. LDL on cardiovascular disease risk
Elias Björnsson, Gothenburg, Sweden
Elias Björnsson, Gothenburg, Sweden
Attacking Scylla or Charybdis: Cholesterol or weight reduction for reduction of atherosclerotic CVD?
Naveed Sattar, Glasgow, UK
Naveed Sattar, Glasgow, UK
Monday 05 May
Sex and gender in cardiovascular disease
Gender medicine: Effects of sex and gender on cardiovascular disease manifestation and outcomes
Vera Regitz-Zagrosek, Berlin, Germany
Vera Regitz-Zagrosek, Berlin, Germany
Deciphering the code: Exploring the influence of biological sex and cardiometabolic disease development
Karen Reue, Los Angeles, USA
Karen Reue, Los Angeles, USA
Acute Coronary Syndromes in the absence of standard modifiable risk factors (SMURFs) and the impact of sex
Gemma Figtree, Sydney, Australia
Gemma Figtree, Sydney, Australia
Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women
Lale Tokgözoğlu, Ankara, Turkey
Lale Tokgözoğlu, Ankara, Turkey
